Hard Gelatin Capsules Compounded and Dispersed in Water in Pediatrics: Real Versus Theoretical Dose Administered
Abstract
Background: In pediatric practice, dose individualization often requires the manipulation of solid oral dosage forms, such as dispersing capsules in water and administering only part of the volume. Despite its frequent use, this practice is poorly documented and may lead to inaccurate dosing. Objectives: This study aimed to assess the actual dose administered when compounded hard gelatin capsules are dispersed in water and partially withdrawn, and to evaluate the influence of different manipulation protocols on dose recovery. Methods: Ten active pharmaceutical ingredients (APIs) routinely compounded as pediatric hard gelatin capsules were studied. Content uniformity was first verified according to European Pharmacopoeia (EP) requirements. One capsule was dispersed in 2 mL of water, and 1 mL was withdrawn using three protocols: (1) no mixing, (2) gentle manual mixing with immediate sampling, and (3) gentle manual mixing followed by a 10 s resting period before sampling. Drug content in the withdrawn volume was quantified using validated HPLC-UV methods. Results are expressed as the mean percentage of the theoretical dose ± standard deviation. Results: All capsules complied with EP content uniformity criteria. However, partial volume administration resulted in marked and protocol-dependent deviations from the theoretical dose. Without mixing, recovered doses ranged from 17% to 58% of the target dose, with high variability. Gentle mixing improved dose recovery, particularly for…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.